Early Change of Extracellular Matrix and Diastolic Parameters in Metabolic Syndrome

Angela B. S. Santos1,2, Mauricio Junges2, Daiane Silvello2, Adriana Macari2, Bruno S. de Araújo2, Beatriz G. Seligman1,2, Bruce B. Duncan2, Luis Eduardo P. Rohde1,2, Nadine Clausell1,2, Murilo Foppa1,2

Hospital de Clínicas de Porto Alegre1; Universidade Federal do Rio Grande do Sul2, Porto Alegre, RS – Brazil

Abstract

Background: Metabolic syndrome (MS) is associated with increased cardiovascular risk. It is not clear whether myocardial changes showed in this syndrome, such as diastolic dysfunction, are due to the systemic effects of the syndrome, or to specific myocardial effects.

Objectives: Compare diastolic function, biomarkers representing extracellular matrix activity (ECM), inflammation and cardiac hemodynamic stress in patients with the MS and healthy controls.

Methods: MS patients (n = 76) and healthy controls (n=30) were submitted to a clinical assessment, echocardiographic study, and measurement of plasma levels of metalloproteinase-9 (MMP9), tissue inhibitor of metalloproteinase-1 (TIMP1), ultrasensitive-reactive-C-Protein (us-CRP), insulin resistance (HOMA-IR) and natriuretic peptide (NT-proBNP).

Results: MS group showed lower E’ wave (10.1 ± 3.0 cm/s vs 11.9 ± 2.6 cm/s, p = 0.005), increased A wave (63.4 ± 14.1 cm/s vs. 53.1 ± 8.9 cm/s; p < 0.001), E/E’ ratio (8.0 ± 2.2 vs. 6.3 ± 1.2; p < 0.001), MMP9 (502.9 ± 237.1 ng / mL vs. 330.4±162.7 ng/mL; p < 0.001), us-CRP (p = 0.001) and HOMA-IR (p < 0.001), but no difference for TIMP1 or NT-proBNP levels. In a multivariable analysis, only MMP9 was independently associated with MS.

Conclusion: MS patients showed differences for echocardiographic measures of diastolic function, ECM activity, us-CRP and HOMA-IR when compared to controls. However, only MMP9 was independently associated with the MS. These findings suggest that there are early effects on ECM activity, which cannot be tracked by routine echocardiographic measures of diastolic function. (Arq Bras Cardiol. 2013;101(4):311-316)

Keywords: Metabolic Syndrome; Risk Factors; Extracellular Matrix; Diastole / physiopathology.

Introduction

The metabolic syndrome (MS) is defined as a combination of several risk factors associated with cardiovascular disease and type 2 diabetes; estimates suggest that this disease affects approximately 35% of the adult population1,2. It is unclear whether myocardial changes associated with the metabolic syndrome are consequences of the systemic effects of the syndrome or due to direct myocardial effects.

The diastolic function evaluation has been used to identify cardiac preclinical changes. Diastolic dysfunction is prevalent in patients with MS, even in the absence of hypertension and diabetes3, and regardless the left ventricular mass4,5. Diastolic dysfunction predicts a worse outcome independently of any other co-morbidity6. In MS, diastolic dysfunction is usually attributed to the increased hemodynamic stress7,8. Alternatively, diastolic dysfunction may also be secondary to changes in the cardiac extracellular matrix resulting from the altered metabolic-inflammatory milieu and glucose metabolism9. Extracellular matrix collagen turnover is tightly regulated by the interaction between metalloproteinases and its plasma tissue inhibitors. Changes in this balance may therefore influence ventricular relaxation and compliance10.

Aiming to a better understand on the underlying processes involved in the cardiovascular abnormalities seen in MS, we studied echocardiographic parameters of diastolic function and quantified plasma levels of metalloproteinase-9 (MMP9), tissue inhibitor of metalloproteinase-1 (TIMP1), ultrasensitive-reactive-C-Protein (us-CRP), insulin resistance (HOMA-IR) and natriuretic peptide (NT-proBNP) in patients with MS compared to healthy controls.

Methods

Population

In this cross-sectional analysis, we selected subjects ranging from 30-55 years of age with MS and healthy controls (CTR). The MS group consisted of all subjects...
recruited for a randomized clinical trial whose protocol and results have already been published[14]. From the initial sample of 471 evaluated volunteers, 76 matched the clinical trial eligibility criteria, which were: Body Mass Index (BMI) ≥ 30 kg/m² and ≤ 40 kg/m², waist circumference ≥ 95 cm and at least two other Metabolic Syndrome criteria according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP/ATP III)[15]. Moreover, all patients had an oral glucose tolerance test that was negative for diabetes. The exclusion criteria were pregnancy, lactation, creatinine ≥ 1.5 mg/dL, musculoskeletal dysfunction, inflammatory or chronic liver disease, thyroid dysfunction and/or use of corticosteroids or anorectic drugs. The baseline data in this group were compared with locally recruited healthy subjects of same gender and age range as that of MS group. The study was approved by the Ethics Committee of our Institution and by the Research Committee, and all participants signed a written informed consent prior to enrollment.

**Clinical Assessment**

Blood pressure and heart rate were measured in triplicate after five minutes at rest using an aneroid sphygmomanometer (Tycos, Welch Allyn, USA), with reported average. Height was measured by a wall-mounted stadiometer, and patients had their weight measured by an electronic scale, wearing light clothes and no shoes. Waist circumference was measured midway between the costal border and the iliac crest.

**Biochemical Analysis**

Blood samples were collected in a fasting state. Insulin was measured via electrochemiluminescence (Roche, Switzerland), and ultra-sensitive plasma C-reactive protein (us-CRP) was measured via immunonephelometry (Roche, Switzerland). The lipid profile was enzymatically measured (us-CRP) was measured via electrochemiluminescence (Roche, Switzerland), and ultra-sensitive plasma C-reactive protein (us-CRP) was measured via electrochemiluminescence (Roche, Switzerland).

**Echocardiographic Study**

Images were obtained with an EnVisor C HD ultrasound system (Philips Medical, Andover, MA, USA) equipped with a 4 to 2 MHz sectorial transducer. The cine loops and static images were digitally recorded, including the M-mode, 2-dimensional, and Doppler modalities. Images were read off-line in a dedicated workstation (ComPACS, Medimatic Srl, Italy) by a single investigator.

The left ventricle (LV) internal dimension, septum and posterior wall thicknesses were measured from the parasternal longitudinal two-dimensional image. The left atrial volume index (LAVi) was measured at the end-ventricular systole from the apical 4-chamber view, using the simple Simpson’s rule and indexed to the body surface area.

The diastolic function was evaluated from the mitral inflow Doppler[14] and tissue Doppler measurements, including: mitral inflow early (E wave) and late (A wave) diastolic velocities, deceleration time (DT) of early diastolic velocity, and early (E’ wave) and late (A’ wave) diastolic annular velocities assessed at the septal mitral anulus. The E/A ratio and the E/E’ ratio were calculated from previous parameters.

All measurements and definitions of relevant cut-offs followed the American Society of Echocardiography recommendations; all of the data were an average of up to 3 consecutive cardiac cycles[16,17]. Left ventricle volume and ejection fraction were calculated using the Teichholz formula. Left ventricle mass index (LVMi) was calculated according to the American Society of Echocardiography formula (16) and indexed to the body height to the power of 2.718. Relative wall thickness (RWT) was defined as (septum + posterior wall thickness)/LV diastolic diameter. The intra-reader reproducibility was assessed in 16 participants as a coefficient of variation (CV) and intra-class correlation (ICC), which were, respectively, E’ wave (CV: 5.2% and ICC: 0.99;95%CI: 0.97-0.99), E wave (CV 4.5% and ICC: 0.98; IC95% 0.96-0.99) and A wave (CV 3.5% and ICC: 0.98;IC95% 0.97-0.99). Additionally, for the two-dimensional measurements, CVs ranged between 8% and 13% and ICCs were above 0.75, whose values are similar to those described in previous studies[19,20].

**ELISA Assays**

Fasting venous blood samples (15 mL) were collected in ethylenediamine tetraacetic acid-containing tubes. Samples were immediately centrifuged at 4°C at 3,000 x g for 20 min, and the plasma removed and stored at –70°C. The plasma samples were all blindly analyzed simultaneously by a laboratory technician. MMP9 and TIMP1 levels were measured in duplicate using commercially available ELISA kits (R & D Systems, Minneapolis, MN, USA). The MMP9 assay sensitivity was <0.156 ng/mL, and the TIMP1 assay sensitivity was <0.08 pmol/L; the intra- and inter-assay coefficients of variation were 6% and 10%, respectively. The NT-proBNP level was also measured with a commercial ELISA kit (Roche Diagnostic, France). The NT-proBNP assay sensitivity was <0.6 pmol/L with intra- and inter-assay coefficients of variation 1.9% and 3.1%, respectively.

**Statistical Analysis**

Results are expressed as mean and SD, or as percentage. Groups were compared with a Chi-square or independent Student’s t test analysis. The associations between continuous variables were tested with Pearson correlation coefficient. Multivariable linear regression analyses models were performed to identify which variables were independently associated with the presence of the MS.

We calculated a sample size of 66 MS and 33 CTR, considering an alpha value of 0.05, a power of 0.8 and 0.6 standard deviation of difference in MMP9 levels between groups. This value was estimated based on...
MMP9 differences described by Tayebjee et al. between hypertensive patients - which frequently showed diastolic dysfunction - and normal controls. P values < 0.05 were considered to be statistically significant. All of the statistical analyses were performed with the SPSS software package (SPSS 15.0 Inc., USA).

Results

We studied 76 patients in the MS group (43.3 ± 7.9 years, 65% male), and 30 healthy controls (CTR; 40.9 ± 6.6 years, 63% male). Further clinical characteristics and laboratory parameters of the groups are shown in Table 1. The MS group, as expected, had increased weight, waist circumference, heart rate, blood pressure, and cholesterol levels when compared with the CTR group.

Left ventricular mass index was higher in the MS group (Table 2). Left atrial volume index and ejection fraction did not differ between groups.

The diastolic function parameters showed that MS had higher A wave (63.4 ± 14.1 cm/s vs. 53.1 ± 8.9 cm/s; p < 0.001), and lower E' wave (10.1 ± 3.0 cm/s vs. 11.9 ± 2.6 cm/s; p = 0.005) compared with controls, but with mean values within the normality range. These differences resulted in a reduced E/A ratio (p = 0.05) and an increased E/E' ratio (p < 0.001) in the MS group. E wave (p = 0.45) and deceleration time (p = 0.98) did not differ between the groups (Table 2).

Extracellular matrix activity biomarkers showed that MMP9 levels were higher in the MS group (502.9 ± 237.1 ng/mL vs. 330.4 ± 162.7 ng/mL; p < 0.001), but with no differences in TIMP1 (210.2 ± 55.6 ng/mL vs. 220.2 ± 57.2 ng/mL; p = 0.41) levels (Figure 1). Insulin resistance measured by HOMA-IR (p < 0.001) and us-CRP (p = 0.001) levels were higher in the MS group, while NT-proBNP levels (p = 0.19) did not show statistically significant difference between the groups (Table 3).

Discussion

In this study, the MS group showed difference in diastolic function parameters and higher levels of HOMA-IR, us-CRP and MMP9 when compared to healthy controls, with no difference in TIMP1 and NT-proBNP levels. However, when adjusted for covariates, only MMP9 was independently associated with the MS.

De las Fuentes et al., investigating echocardiographic parameters of diastolic function in MS patients, showed increased A wave, decreased E’ wave, and no difference in E wave. Although we have found similar results for these parameters, they were not independently associated with MS after adjustment for covariates, whereas MMP9 was still significant. We could infer that, in the early phases of metabolic syndrome, modulations in ECM activity measured by the increase in MMP9 levels, anticipate measurable changes in cardiac pressures measured by diastolic Doppler parameters, NT-proBNP levels or left atrial dimensions, which are frequently used as surrogate markers of loading conditions.

Extracellular matrix activity has been associated with relaxation and LV stiffness. The increased MMP9 in the metabolic syndrome may represent a collagen turnover state in the extracellular matrix, which may contribute to adverse ventricular remodeling and left ventricular stiffness. Gonçalves et al., studying 25 patients with MS and 25 healthy controls, found increased levels of both MMP9 and TIMP1 in the MS group; reflecting the advanced dysmetabolic state in those patients compared to our sample.
Table 2 - Echocardiographic parameters and diastolic function of the metabolic syndrome (MS) and healthy control (CTR) groups

| Parameter                  | MS (n = 76)   | CTR (n = 30)  | p    |
|----------------------------|---------------|---------------|------|
| LVMI (g/m²)                | 37.8(7.5)     | 32.4(7.2)     | 0.001|
| Relative Wall Thickness    | 0.39(0.07)    | 0.36(0.05)    | 0.17 |
| LV Ejection Fraction (%)   | 68.5(5.4)     | 66.9(7.1)     | 0.22 |
| LAVI (mL/m²)               | 24.3(6.0)     | 25.6(5.9)     | 0.35 |
| E wave (cm/s)              | 76.9(15.7)    | 74.4(15.6)    | 0.45 |
| A wave (cm/s)              | 63.4(14.1)    | 53.1(8.9)     | < 0.001|
| Deceleration time (ms)     | 205.2(28.6)   | 205.3(35.3)   | 0.98 |
| E' wave (cm/s)             | 10.1(3.0)     | 11.9(2.6)     | 0.005|
| A' wave (cm/s)             | 11.0(2.3)     | 10.1(1.9)     | 0.04 |
| E/A ratio                  | 1.26(0.38)    | 1.42(0.3)     | 0.05 |
| E/E' ratio                 | 8.0(2.2)      | 6.3(1.2)      | < 0.001|

Values showed as mean (SD). LVMI: left ventricular mass index; LAVI: left atrial volume index; E wave: mitral inflow early diastolic velocity; A wave: mitral inflow late diastolic velocity; E' wave: early diastolic annular velocity; A' wave: late diastolic annular velocity.

Table 3 – Circulating biomarkers in the metabolic syndrome (MS) and healthy control (CTR) groups

| Biomarker          | MS (n = 76)   | CTR (n = 30)  | p    |
|--------------------|---------------|---------------|------|
| MMP9 (ng/mL)       | 502.9(237.1)  | 330.4(162.7)  | < 0.001|
| TIMP1 (ng/mL)      | 210.2(55.6)   | 220.2(57.2)   | 0.41 |
| NT-proBNP (ng/mL)  | 29.9(21.9)    | 23.6(21.7)    | 0.19 |
| HOMA-IR units      | 3.4(1.6)      | 1.6(0.8)      | < 0.001|
| us-CRP (mg/dL)     | 3.9(3.6)      | 1.5(1.5)      | 0.001|

Values showed as mean (SD). MMP9: metalloproteinase 9; TIMP1: Plasma Tissue Inhibitor of Metalloproteinase-1 levels (TIMP1); NT-proBNP: natriuretic peptide; HOMA-IR: homeostasis model assessment for insulin resistance; us-CRP: ultrasensitive C-reactive protein.
Oversimplification of multifactorial mechanisms based upon a limited subset of markers is inherent to this study design and precludes causal inferences. A potential bias of this analysis was the non-blinded echocardiographic acquisition for the groups, minimized by the off-line reading by a single investigator. It must also be brought to attention the potential role of newer technologies, such as the speckle tracking, which could more accurately find these early adaptive changes related to the metabolic syndrome.

Conclusions

We have found that patients with MS showed differences in echocardiographic measures of diastolic function, in ECM activity measured by MMP9, us-CRP and HOMA-IR when compared to healthy controls. However, only MMP9 was independently associated with the MS. These findings suggest that there are early effects on extracellular matrix activity in metabolic syndrome, which cannot be tracked by routine echocardiographic measures of diastolic function.

Author contributions

Conception and design of the research: Santos ABS, Junges M, Silvello D, Macari A, Araújo BS, Seligman BG, Duncan BB, Clausell N, Foppa M; Acquisition of data: Santos ABS, Junges M, Silvello D, Macari A, Araújo BS, Seligman BG, Foppa M; Analysis and interpretation of the data: Santos ABS, Junges M, Silvello D, Seligman BG, Rohde LEP, Clausell N, Foppa M; Statistical analysis: Santos ABS, Foppa M; Obtaining funding: Santos ABS, Duncan BB, Foppa M; Writing of the manuscript: Santos ABS, Seligman BG, Duncan BB, Clausell N, Foppa M; Critical revision of the manuscript for intellectual content: Santos ABS, Seligman BG, Duncan BB, Rohde LEP, Clausell N, Foppa M.

Potential Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Sources of Funding

This study was funded by CNPq and FIPe/HCPA.

Study Association

This article is part of the thesis of master submitted by Angela Barreto Santiago Santos from Universidade Federal do Rio Grande do Sul.

References

1. Ford ES. Prevalence of the Metabolic Syndrome Defined by the International Diabetes Federation among adults in the U.S. Diabetes Care. 2005;28(11):2745-9.
2. Ford ES, Li C, Zhao G. Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. J Diabetes. 2010;2(3):180-93.
3. Ajaza B, Ammar KA, Lopez-Jimenez F, Redfield MM, Jacobsen SJ, Rodeheffer RJ. Abnormal cardiac structure and function in the metabolic syndrome: a population-based study. Mayo Clin Proc. 2008;83(12):1150-7.
4. de las Fuentes L, Brown AL, Mathews SJ, Waggoner AD, Soto PF, Gropler RJ, et al. Matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res. 2000;46(2):214-24.
18. de Simone G, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol. 1995;25(5):1056-62.

19. Patel DA, Srinivasan SR, Chen W, Berenson GS. Influence of the metabolic syndrome versus the sum of its individual components on left ventricular geometry in young adults (from the Bogalusa Heart Study). Am J Cardiol. 2009;104(1):69-73.

20. Grothues F, Smith GC, Moon JC, Bellenger NG, Collins P, Klein HU, et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol. 2002;90(1):29-34.

21. Tayebjee MH, Nadar SK, MacFadyen RJ, Lip GY. Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension: relationship to tissue Doppler indices of diastolic relaxation. Am J Hypertens. 2004;17(9):770-4.

22. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J. 1998;135(5 Pt 1):825-32.

23. Tamura H, Watanabe T, Nishiyama S, Sasaki S, Azimoto T, Takahashi H, et al. Increased left atrial volume index predicts a poor prognosis in patients with heart failure. J Card Fail. 2011;17(3):210-6.

24. Gonçalves FM, Jacob-Ferreira AL, Gomes VA, Casella-Filho A, Chagas AC, Marcaccini AM, et al. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome. Clin Chim Acta. 2009;403(1-2):173-7.